Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4440818 | 0.93 | ALDH1A1 (0.33) | ALDH1A1TSHRPDE7AEPAS1VEGFA | |
| SCHEMBL2880917 | 0.80 | TSHR (0.32) | TSHRTP53CYP3A4 | |
| SCHEMBL2943368 | 0.79 | MEN1 (0.38) | ALDH1A1TSHRPDE7AEPAS1VEGFA | |
| SCHEMBL2878659 | 0.77 | ALDH1A1 (0.47) | ALDH1A1TSHRPDE7AMEN1KMT2A | |
| Iodide SCHEMBL4440824 | 0.77 | ALDH1A1 (0.31) | ALDH1A1TSHREPAS1VEGFA | |
| SCHEMBL4786052 | 0.75 | MEN1 (0.36) | ALDH1A1TSHRPDE7AEPAS1VEGFA | |
| SCHEMBL22326087 | 0.69 | PDE7A (0.42) | ALDH1A1PDE7AMEN1KMT2AHTT | |
| SCHEMBL22325952 | 0.68 | EPAS1 (0.46) | ALDH1A1PDE7AEPAS1MEN1KMT2A | |
| SCHEMBL31330060 | 0.68 | ALDH1A1 (0.42) | ALDH1A1TSHRPDE7AMEN1KMT2A | |
| SCHEMBL240637 | 0.68 | PTGER4 (0.48) | ALDH1A1TSHRMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121638-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ANTHONY NEVILLE J | 2010-11-11 | — | — | US | disclosed |
| US-7781454-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2121638-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME LLC | 2008-11-06 | — | — | US | disclosed |
| WO-2008076225-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | RNGTT, RRM2B, RRM2 | ALDH1A1 2863/4885TSHR 2632/4885PDE7A 1715/4885 |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RNGTT, RRM2B, RRM2 | ALDH1A1 2863/4885TSHR 2632/4885PDE7A 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.